GlaxoSmithKline to commence Phase 2 studies of GSK2586184 JAK1 molecule
GSK is expecting to assess the safety and efficacy profile of varying doses of GSK2586184 in a multi-center placebo-controlled Phase 2 study scheduled for 12 weeks, in SLE
Ultragenyx Pharmaceutical has received accelerated approval from the US Food and Drug Administration (FDA) for its gene therapy, Genglycos (pariglasgene brecaparvovec-opnr), to treat glycogen storage disease type Ia (GSDIa).
Glenmark Biologics Research Centre in La Chaux-de-Fonds, Switzerland, discovered GBR 830. GBR 830 is a potent therapeutic option for patients suffering from immune pathologies including autoimmune diseases like
The partnership will leverage RaQualia’s core expertise in drug discovery and development, and Interprotein’s platform technology, INTerprotein’s Engine for New Drug Design (INTENDD). Under the agreement, RaQualia will